Latest Health News

REA Group Ltd has announced a fully franked ordinary dividend of AUD 1.10 per share for the half-year ending December 2024, signaling continued shareholder returns.

Midway Limited’s shares have been suspended from trading following Federal Court approval of its acquisition by River Capital’s RCM BidCo Pty Ltd, marking a pivotal moment for the timber producer.

Little Green Pharma has finalized the acquisition of Health House, a key medicinal cannabis distributor, for a fraction of its previous valuation, marking a strategic move to deepen vertical integration.

Vanadium Resources Limited (ASX: VR8) has voluntarily suspended trading of its shares pending a significant announcement on funding arrangements, signaling a pivotal moment for the company’s financial trajectory.

Audeara Limited has landed a significant US$917,000 follow-up purchase order from a global music instrument manufacturer, reinforcing the commercial viability of its hearing technology and expanding its licensing footprint.

Biome Australia has partnered with the Food and Beverage Accelerator (FaBA) to jointly develop its promising BMB18 probiotic strain, leveraging $50 million in Australian government funding while retaining full IP ownership.

Delorean Corporation has marked a pivotal quarter with the Financial Investment Decision for its SA1 Bioenergy Project and steady progress on the Yarra Valley Water facility, underpinning its transition to infrastructure ownership in Australia's bioenergy sector.

Magnum Mining and Exploration Limited has announced a pro-rata non-renounceable entitlement offer to raise up to $1.94 million, aiming to fund exploration at its Palmares and Buena Vista projects. The offer includes new shares and free options, presenting both opportunity and dilution risks for shareholders.

Xref Limited reported a solid 10% revenue increase to $10.9 million in H1 FY2025, even as a proposed acquisition by SEEK was narrowly rejected by shareholders. The company plans to continue its growth trajectory as an independent ASX-listed entity with new product launches on the horizon.

Bio-Gene Technology Limited has secured A$3 million in U.S. Department of Defense grants to accelerate development of its two nature-derived insecticides, Flavocide and Qcide, targeting both military and civilian markets.

Pro Medicus has inked a $53 million, seven-year contract with BayCare to deploy its Visage 7 cloud-based imaging platform across Florida’s largest healthcare system, marking a major step in its North American expansion.

Argenica Therapeutics reports compelling preclinical evidence that its lead candidate ARG-007 significantly reduces brain cell damage and inflammation in moderate traumatic brain injury models, marking a promising step toward new TBI treatments.